DoD Pancreatic Cancer, Idea Development Award | W81XWH 20 PCARP IDA

Opportunity Information: Apply for W81XWH 20 PCARP IDA

The Department of Defense, through the Pancreatic Cancer Research Program (PCARP) managed by the US Army Medical Research Acquisition Activity (USAMRAA), offered the FY20 Pancreatic Cancer Idea Development Award (Funding Opportunity Number W81XWH-20-PCARP-IDA) to push forward bold, high-risk/high-reward pancreatic cancer research. The core purpose of the award is to help investigators develop genuinely new ideas that could unlock critical discoveries or create major advances that speed progress toward better outcomes for people with pancreatic cancer. In practice, this mechanism is meant to generate impactful data and open up new lines of investigation rather than simply extending existing work.

A central expectation is clear and meaningful impact. Applications are supposed to make the case that the proposed project will contribute something important and original to pancreatic cancer research, with a plausible path toward improving patient outcomes. Even if the work is not immediately clinical, the applicant is expected to explain how the results could matter for the field and for patient care down the road. Reviewers are looking for a strong rationale for why the project, if successful, would move understanding or management of pancreatic cancer forward in a noticeable way.

Innovation is treated as a defining requirement, not a bonus. The opportunity emphasizes research that introduces a new paradigm, challenges existing assumptions, reframes a known problem from a fresh angle, or uses highly creative approaches. Innovation can come from the underlying concept, the tools and technologies applied, the study design, or smart adaptations of existing methods to a new context. What the program does not want is incremental research that amounts to a small next step built directly on previously published work; proposals need to show that they are taking a real swing at something different and potentially transformative.

Team composition also matters. The solicitation highlights personnel as a crucial element and requires that at least one member of the research team bring demonstrated pancreatic cancer experience, typically shown through recent publications and research funding. It also encourages inclusion of a biostatistician, signaling that rigorous study design, appropriate powering where relevant, and solid analytical planning are important review considerations.

While the award is aimed at new ideas, it is not intended for purely speculative concepts without support. Proposed research must be grounded in preliminary data. Importantly, the preliminary data do not have to come from pancreatic cancer specifically; they can originate from outside the pancreatic cancer field as long as the proposed project itself has direct relevance to pancreatic cancer. Alongside the preliminary results, applications are expected to present a sound scientific rationale built through logical reasoning and a critical, well-supported reading of the existing literature.

A notable feature is the Partnering PI option designed to help early-career investigators enter and build a career in pancreatic cancer research. Under this structure, an experienced investigator serves as the Initiating PI and formally mentors and collaborates with an Early-Career Investigator who serves as the Partnering PI. The program indicates that this partnered approach may qualify for a higher funding level, and it places responsibility for most administrative aspects of submission on the Initiating PI. At the same time, both PIs are expected to play substantial roles in shaping the science, including the project narrative, statement of work, and other required application components. If funded, each PI is named on an individual award within the recipient organization, and the opportunity explicitly encourages multidisciplinary and multi-organizational collaborations.

From an administrative standpoint, the award fell under CFDA 12.420 and was offered as either a grant or cooperative agreement within the Science and Technology/Research and Development category. Eligibility was broadly described as unrestricted (open to any entity type), subject to any additional clarifications in the full announcement. The opportunity was posted July 1, 2020, with an original closing date of November 20, 2020, and it anticipated making around three awards. The listing shows an award ceiling of 0, which typically indicates that applicants needed to refer to the full funding announcement for specific budget limits or that limits varied by option (including the partnered PI structure).

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Pancreatic Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jul 01, 2020.
• Applicants must submit their applications by Nov 20, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PCARP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: